Gabather AB

Equities

GABA

SE0010869552

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:13:21 2024-06-07 am EDT			5-day change	1st Jan Change
1.815 ^SEK	-0.27%		+9.67%	+28.72%

May. 30	Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 10	Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	CI

BioStock Studio: Gabather gives clinical trial update

March 25, 2021 at 04:38 am EDT

Gabather's top candidate GT-002 for treating psychiatric or mood disorders like depression, anxiety, and schizophrenia is currently in the early stages of clinical development. The company is planning a key target engagement study in healthy volunteers aimed at showing how GT-002 modulates brain activity at both the functional and regional levels of the brain. The company's CEO Michael-Robin Witt joined BioStock via link to tell us more about GT-002 and give us an update on the ongoing clinical trial.

Watch the interview with Gabather's CEO Michael-Robin Witt at biostock.se:

https://www.biostock.se/2021/03/gabather-gives-clinical-trial-update/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/gabather-ab/r/biostock-studio--gabather-gives-clinical-trial-update,c3314045

Latest news about Gabather AB

Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 30	CI
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	Apr. 10	CI
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	Mar. 18	MT
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders	Mar. 18	CI
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study	Mar. 07	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002	Dec. 14	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	23-10-12	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application	23-04-13	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-08	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Gabather Secures Notice Of Allowance For US Patent Claims Covering Neuropsychiatric Drug Synthesis	22-06-07	MT
Gabather Receives Approval to Start the EEG/fMRI Target Engagement Study with the Drug Candidate GT-002	22-05-17	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Gabather AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-17	CI
Gabather AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-17	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-28	CI
Gabather AB Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-26	CI
Gabather AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
Gabather AB Gives Clinical Trial Update	21-03-25	CI
Gabather AB Enters into A Research Collaboration to Investigate GT-002	21-03-24	CI

Chart Gabather AB

Duration

Period

More charts

Company Profile

Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimerâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-06-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GABATHER AB	+28.72%	3.3M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-13.31%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.39B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.1B

Bio Therapeutic Drugs